Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
Details
Publication Year 2017-08-04,Volume 7,Issue #1,Page 7284
Journal Title
Scientific Reports
Publication Type
Journal Article
Abstract
The majority of routinely given vaccines require two or three immunisations for full protective efficacy. Single dose vaccination has long been considered a key solution to improving the global immunisation coverage. Recent infectious disease outbreaks have further highlighted the need for vaccines that can achieve full efficacy after a single administration. Viral vectors are a potent immunisation platform, benefiting from intrinsic immuno-stimulatory features while retaining excellent safety profile through the use of non-replicating viruses. We investigated the scope for enhancing the protective efficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of malaria by co-administering it with vaccine adjuvants. Out of 11 adjuvants, only two, Abisco(R)-100 and CoVaccineHTTM, enhanced vaccine efficacy and sterile protection following malaria challenge. The CoVaccineHTTM adjuvanted vaccine induced significantly higher proportion of antigen specific central memory CD8+ cells, and both adjuvants resulted in increased proportion of CD8+ T cells expressing the CD107a degranulation marker in the absence of IFNgamma, TNFalpha and IL2 production. Our results show that the efficacy of vaccines designed to induce protective T cell responses can be positively modulated with chemical adjuvants and open the possibility of achieving full protection with a single dose immunisation.
Publisher
Springer Nature
Research Division(s)
Population Health And Immunity
PubMed ID
28779101
Open Access at Publisher's Site
http://www.nature.com/articles/s41598-017-07246-0
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-08-30 02:22:30
Last Modified: 2017-09-04 03:05:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙